B-Cell Depleter Nabs Phase III Win in Autoimmune Kidney Disease

(MedPage Today) -- The B-cell depleting agent obinutuzumab (Gazyva) was superior to the immunosuppressant tacrolimus in inducing remissions in primary membranous nephropathy, the global phase III MAJESTY trial showed.
By week 104, 37% of patients...